Strides Pharma Science

US Market Dependency Will Strain Margins Yet Yield Opportunity

AnalystLowTarget

Not Invested

Community Contributor

Published

03 Aug 25

AnalystLowTarget's Fair Value

₹937.00

13.1% undervalued

03 Aug

₹814.55

-46.0%

1.9%

-46.0%

1.9%

You can edit this narrative until Aug 3 10:40 PM. Then, changes will post as Updates.

Author's Valuation

₹93713.1% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

₹937

13.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

12.85%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.73%

Calculation

₹9.38b

Earnings '28

13.17x

PE Ratio '28

₹123.49b

Market Cap '28

₹123.49b

Market Cap '28

92.75m

No. shares '28

₹1.33k

Share Price '28

₹1.33k Share Price '28

Discounted to 2025 @ 12.73% p.a.

₹929.47

Fair Value '25